Western Regional Blog – BC, YK, AB, NWT and Nunavut
“A promising approach to treat ovarian cancer is oncolytic virus therapy using measles vaccine virus (MeV). Arming of MeV with a prodrug-converting suicide-gene in combination with prodrug treatment highly enhanced ovarian cancer cell killing. Virotherapy of ovarian cancer using armed measles vaccine virus warrants further clinical investigation.”
A.D. Hartkopf, S. Bossow, J. Lampe, M. Zimmermann, F.-A. Taran, D. Wallwiener, T. Fehm, M. Bitzer, U.M. Lauer
To preclinical assess the feasibility of combining oncolytic measles vaccine virus (MeV) with suicide gene therapy for ovarian cancer treatment.
We genetically engineered a recombinant MeV armed with a yeast-derived bifunctional suicide gene that encodes for cytosine deaminase and uracil phosphoribosyltransferase (MeV-SCD). From this suicide gene, a chimeric protein is produced that converts the non-toxic prodrug 5-fluorocytosine (5-FC) into highly cytotoxic 5-fluorouracil (5-FU) and directly into 5-fluorouridine monophosphate (5-FUMP) thereby bypassing an important mechanism of chemoresistance to 5-FU.
MeV-SCD was demonstrated to infect, replicate in and effectively lyse not only human ovarian cancer cell lines, but also primary tumor cells (albeit at lower efficiencies) that were derived from malignant ascites of ovarian cancer patients. Addition of the prodrug 5-FC significantly enhanced cell killing. Importantly, precision-cut tumor slices of human ovarian cancer patient specimens were efficiently infected with MeV-SCD. The prodrug-converting enzyme SCD was expressed by all infected tumor slices, thereby ensuring provision of the suicide gene arming function in patient-derived materials.
With respect to safety and therapeutic impact, arming of oncolytic measles vaccine virus warrants further clinical investigation for ovarian cancer treatment